TY - JOUR
T1 - Successful salvage treatment of resistant acute antibody-mediated kidney transplant rejection with eculizumab
AU - Khan, Saif A.
AU - Al-Riyami, Dawood
AU - Al-Mula Abed, Yasser W.
AU - Mohammed, Saja
AU - Al-Riyami, Marwa
AU - Al-Lawati, Nabil M.
PY - 2016/8
Y1 - 2016/8
N2 - Antibody-mediated rejection (ABMR) jeopardises short- and long-term transplant survival and remains a challenge in the field of organ transplantation. We report the first use of the anticomplement agent eculizumab in Oman in the treatment of a 61-year-old female patient with ABMR following a living unrelated kidney transplant. The patient was admitted to the Sultan Qaboos University Hospital in Muscat, Oman, in 2013 on the eighth day post-transplantation with serum creatinine (Cr) levels of 400 µmol/L which continued to rise, necessitating haemodialysis. A biopsy indicated ABMR with acute cellular rejection. No improvement was observed following standard ABMR treatment and she continued to require dialysis. Five doses of eculizumab were administered over six weeks with a subsequent dramatic improvement in renal function. The patient became dialysis-free with serum Cr levels of 119 µmol/L within four months. This case report indicates that eculizumab is a promising agent in the treatment of ABMR.
AB - Antibody-mediated rejection (ABMR) jeopardises short- and long-term transplant survival and remains a challenge in the field of organ transplantation. We report the first use of the anticomplement agent eculizumab in Oman in the treatment of a 61-year-old female patient with ABMR following a living unrelated kidney transplant. The patient was admitted to the Sultan Qaboos University Hospital in Muscat, Oman, in 2013 on the eighth day post-transplantation with serum creatinine (Cr) levels of 400 µmol/L which continued to rise, necessitating haemodialysis. A biopsy indicated ABMR with acute cellular rejection. No improvement was observed following standard ABMR treatment and she continued to require dialysis. Five doses of eculizumab were administered over six weeks with a subsequent dramatic improvement in renal function. The patient became dialysis-free with serum Cr levels of 119 µmol/L within four months. This case report indicates that eculizumab is a promising agent in the treatment of ABMR.
KW - Case report
KW - Complement activation
KW - Eculizumab
KW - Kidney transplantation
KW - Oman
KW - Transplantation rejection
UR - http://www.scopus.com/inward/record.url?scp=84983287431&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84983287431&partnerID=8YFLogxK
U2 - 10.18295/squmj.2016.16.03.020
DO - 10.18295/squmj.2016.16.03.020
M3 - Article
AN - SCOPUS:84983287431
SN - 2075-051X
VL - 16
SP - e371-e374
JO - Sultan Qaboos University Medical Journal
JF - Sultan Qaboos University Medical Journal
IS - 3
ER -